AnasYounesMD

Oncology • New York, NY

Senior VP, and Global Head of Hematology R&D at AstraZeneca

Join to view full profile

Dr. Younes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Younes' full profile

Already have an account?

Office
430 E 29th St,
New York, NY 10016
Phone+1 301-398-0000

Summary

Anas Younes

Education & Training

Memorial Sloan-Kettering Cancer CenterFellow, medical oncology, 1989 - 1992
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1986 - 1989
University of ToledoResidency, Pathology-Anatomic and Clinical, 1985 - 1986
Damascus University Faculty of MedicineClass of 1983

Certifications & Licensure

NY State Medical License 1988 - 2027
NJ State Medical License 2019 - 2021
TX State Medical License 1992 - 2013
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

top doctor castle connoly, 2017
Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease Start of enrollment: 1998 Feb 01
Completed
Phase 2
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2000 Sep 01
Completed
Phase 2
A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma Start of enrollment: 2001 May 18
Completed
Phase 2
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy Start of enrollment: 2001 Nov 01
Completed
Phase 3
Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma Start of enrollment: 2002 Apr 01
Completed
Phase 2
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma Start of enrollment: 2005 Feb 01
Completed
Phase 2
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease Start of enrollment: 2005 Jun 22
Withdrawn
Phase 2
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma Start of enrollment: 2003 Sep 01
Completed
Phase 2
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2004 Mar 01
Completed
Phase 2
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2006 Sep 01
Terminated
Phase 2
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies Start of enrollment: 2006 Nov 01
Completed
Phase 1
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma Start of enrollment: 2006 May 01
Unknown status
Phase 1, Phase 2
Rituximab and ABVD for Hodgkin's Patients Start of enrollment: 2001 Mar 01
Completed
Phase 2
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma Start of enrollment: 2007 Dec 01
Completed
Phase 1
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma Start of enrollment: 2008 Mar 19
Completed
Phase 2
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies Start of enrollment: 2008 Jul 01
Completed
Phase 1
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma Start of enrollment: 2008 Nov 01
Completed
Phase 1, Phase 2
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma Start of enrollment: 2009 Nov 01
Completed
Phase 1, Phase 2
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma Start of enrollment: 2009 Sep 01
Terminated
Phase 3
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma Start of enrollment: 2011 Jan 31
Completed
Phase 1, Phase 2
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma Start of enrollment: 2010 Oct 01
Completed
Phase 1
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Start of enrollment: 2010 Dec 01
Completed
Phase 2
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies Start of enrollment: 2010 Dec 01
Completed
Phase 2
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease Start of enrollment: 1996 Jul 01
Completed
Phase 2
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) Start of enrollment: 2014 Aug 12
Completed
Phase 2
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML Start of enrollment: 2014 Oct 01
Withdrawn
Phase 1
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL Start of enrollment: 2015 Nov 16
Completed
Phase 1
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma Start of enrollment: 2016 May 09
Completed
Phase 1
Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2017 Apr 14
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma.
Ana Portelinha, Shenqiu Wang, Sara Parsa, Man Jiang, Alexander N Gorelick
The Journal of Experimental Medicine. 2024-10-07
1 citations
to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
Haematologica. 2024-08-01
1 citations
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
Haematologica. 2024-04-01

Journal Articles

Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma
Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
NOXA Genetic Amplification or Pharmacologic Induction Primes Lymphoma Cells to BCL2 Inhibitor-Induced Cell Death
Anas Younes, MD, Proceedings of the National Academy of Sciences
Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II Study
Francesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica

Abstracts/Posters

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial
Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma
Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated...
Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Dual Inhibition of MCL1 and BCL2 in Lymphoma Using Tumor Targeted Nanoparticles
Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analys...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Taking on New Challenges: 8 Questions with Gilles SallesDecember 23rd, 2020
Physicians’ Education Resource® Presents the 3rd Annual Live Medical Crossfire®: Hematologic MalignanciesJune 20th, 2019
Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesOctober 4th, 2018
Join now to see all